# In phase 2 trial, novel therapy significantly reduced triglyceride levels

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-phase-trial-therapy-significantly-triglyceride.html) · 2026-11-09 · Medicine
Page: https://themorning.science/story/in-phase-2-trial-novel-therapy-significantly-reduced-triglyceride-levels-754e9e1e7f1d32ea
Kind: research · Impact: medium

## In brief

- A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers tested MAR001, a monoclonal antibody therapy.
- The trial found MAR001 significantly reduced triglyceride levels within 12 weeks in patients with high triglyceride levels.

## Why it matters

It reports early clinical evidence for a new antibody-based way to lower triglycerides, a lipid linked to cardiovascular risk, though it is a phase 2 result and not yet an approved treatment.

## Coverage

- [In phase 2 trial, novel therapy significantly reduced triglyceride levels](https://medicalxpress.com/news/2026-11-phase-trial-therapy-significantly-triglyceride.html) — Medical Xpress - latest medical and health news stories, 2026-11-09

Tags: triglycerides, monoclonal antibody, clinical trial, cardiovascular, lipids

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science